Myriad Genetics, Inc.


Market Cap$2.11B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Myriad Genetics, Inc.Myriad Genetics, Inc.-90%-31%30.1

Target Price by Analysts

17.2% upsideMyriad Genetics Target Price DetailsTarget Price

Current Fair Value

111% downside

Overvalued by 111% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.11 Billion
Enterprise Value$2.04 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-2.76
Outstanding Shares90,507,981
Avg 30 Day Volume643,177


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-8.99
Price to Sales2.99
Price to Book Ratio2.99
Enterprise Value to Revenue2.64
Enterprise Value to EBIT-16.98
Enterprise Value to Net Income-9
Total Debt to Enterprise0.02
Debt to Equity0.05

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Myriad Genetics, Inc.

2,600 employees
CEO: R. Bryan Riggsbee

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...